SETBP1 mutations in 415 patients with primary myelofibrosis or chronic myelomonocytic leukemia: independent prognostic impact in CMML.
about
Therapeutic approaches in myelofibrosis and myelodysplastic/myeloproliferative overlap syndromesCytogenetic and molecular abnormalities in chronic myelomonocytic leukemiaRationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosisEvaluation of a father and son with atypical chronic myeloid leukemia with SETBP1 mutations and a review of the literatureA novel BCR-ABL1 fusion gene with genetic heterogeneity indicates a good prognosis in a chronic myeloid leukemia case.ASXL1 mutations are frequent and prognostically detrimental in CSF3R-mutated chronic neutrophilic leukemia.Clinical significance of CSF3R, SRSF2 and SETBP1 mutations in chronic neutrophilic leukemia and chronic myelomonocytic leukemia.Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome.Genomic Profiling of Chronic Myelogenous Leukemia: Basic and Clinical ApproachCSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia.Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study.Molecular genetics of chronic neutrophilic leukemia, chronic myelomonocytic leukemia and atypical chronic myeloid leukemia.Impact of TET2, SRSF2, ASXL1 and SETBP1 mutations on survival of patients with chronic myelomonocytic leukemiaPrognostic significance of SETBP1 mutations in myelodysplastic syndromes, chronic myelomonocytic leukemia, and chronic neutrophilic leukemia: A meta-analysis.Overlapping SETBP1 gain-of-function mutations in Schinzel-Giedion syndrome and hematologic malignancies.Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemiaAn International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms.Chronic myelomonocytic leukemia: Forefront of the field in 2015.Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS.Somatic SETBP1 mutations in myeloid malignanciesThe new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatmentClinical management of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.Age-related mutations and chronic myelomonocytic leukemia.Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia.Chronic myelomonocytic leukemia: 2013 update on diagnosis, risk stratification, and management.I walk the line: how to tell MDS from other bone marrow failure conditions.Molecular pathogenesis of atypical CML, CMML and MDS/MPN-unclassifiable.Chronic Myelomonocytic Leukemia: a Genetic and Clinical Update.Chronic neutrophilic leukemia 2016: Update on diagnosis, molecular genetics, prognosis, and management.Genomics of chronic neutrophilic leukemia.Somatic SETBP1 mutations in myeloid neoplasms.Neutrophilic leukocytosis in advanced stage polycythemia vera: hematopathologic features and prognostic implications.Predictors of survival in refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) and the role of next-generation sequencing.Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia.SETBP1 mutations as a biomarker for myelodysplasia /myeloproliferative neoplasm overlap syndrome.Only SETBP1 hotspot mutations are associated with refractory disease in myeloid malignancies.Therapy for Chronic Myelomonocytic Leukemia in a New Era.Myelodysplastic/myeloproliferative neoplasms: a disease in need of recognition.Granulocyte colony-stimulating factor receptor T595I (T618I) mutation confers ligand independence and enhanced signaling.SETBP1 mutation analysis in 944 patients with MDS and AML.
P2860
Q26752940-E8CFCC60-C277-44EC-8B32-5F2ACD77C388Q26768600-64456027-EFA3-4571-A812-24C573358BE1Q26772881-305A3169-73D9-470B-95BB-8F8C50689C1DQ28083489-148265FF-9CCA-4628-96E6-A1C48CC89013Q30152631-0B04F3F7-5257-46C4-A3BD-E35EDCA7A078Q33421772-EA2D6512-8520-4318-9C01-1395F1C156BFQ33591367-116828F7-790C-4C6C-AC14-CD5BE1244ECAQ33600822-E8CAA094-1812-4BD2-8E22-B56BF8402712Q33888064-0CFBE31C-ACB1-4BE0-97A3-91E655AF3BA4Q33909621-00370D47-581B-4769-AA46-BF1BBE2EE038Q34037065-ED439433-70AC-4019-8B30-2C4B23C9B69EQ34700714-9EFDF051-77DE-4506-8BB8-5942EB7AF6CEQ35654081-20BA66FB-82F9-490B-9945-9D4BD1FBA351Q36270003-6B9BE1AC-66CD-4A98-9D79-252E587023EFQ36323864-557C0E84-5591-4E09-88FB-EF0C621923C4Q36548070-0A8C5AFE-13BB-44B8-ACA8-6BB677A49652Q36708989-1CD4A750-DEFF-4F48-AFF5-17D326B09267Q36876853-A2D9991D-FBF6-4AFC-8459-040D060198E0Q37046592-23B653B4-A91C-48D3-A035-21CBB9132752Q37060418-9CFEBD82-2610-4095-B687-7EBA4CBB582DQ37151676-2AB4F14B-1C03-4194-8440-FD7BD3170EF7Q37349392-D623C109-286E-44AE-BC7A-164FB1664D4FQ37395779-C208DE98-DF1F-4DDA-A619-2B8F594D3DC0Q37707099-07193765-295B-4FB8-A5A1-A4A1661028F6Q38130476-1E28D144-C651-4228-B219-0738012D548EQ38235622-83A33D24-31F2-4EA4-8B8E-7275E80A47F1Q38248429-A8D13EA3-C276-4773-AF81-FA44EDD6E974Q38540013-26583497-F587-4AAD-934C-4B8CEFEA382CQ38678287-060DCC39-5809-48A2-91E2-A378B1D8FE77Q39059515-76D9673B-68D7-4198-93BA-157C46FFB42BQ39266051-A32D9E45-44C9-4A91-B165-7FCFDF92EC52Q40577443-7EEA9FFB-DB71-4B5E-B30A-168F0A66E567Q40911131-5C343F3E-7443-4803-BD2F-E82A891C250FQ41183059-05756FEE-04C2-4454-B634-41705AF4DFB1Q47140333-0A421AD8-705C-427B-8914-A39E8B829823Q47797877-A1B10122-444E-47E3-B6D4-139DCCF9172EQ47853133-7AD6343E-5BE6-4D8F-9F98-A15FD06D38C5Q50891297-2FF66DF2-4478-46E9-86C8-293B70FB4567Q50934344-C44FDFAD-8E91-4E78-8166-B86FE191764DQ51016169-D30C04C5-EB71-4BB8-A556-25EFC45B4B1F
P2860
SETBP1 mutations in 415 patients with primary myelofibrosis or chronic myelomonocytic leukemia: independent prognostic impact in CMML.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
SETBP1 mutations in 415 patien ...... ent prognostic impact in CMML.
@en
SETBP1 mutations in 415 patien ...... ent prognostic impact in CMML.
@nl
type
label
SETBP1 mutations in 415 patien ...... ent prognostic impact in CMML.
@en
SETBP1 mutations in 415 patien ...... ent prognostic impact in CMML.
@nl
prefLabel
SETBP1 mutations in 415 patien ...... ent prognostic impact in CMML.
@en
SETBP1 mutations in 415 patien ...... ent prognostic impact in CMML.
@nl
P2093
P2860
P356
P1433
P1476
SETBP1 mutations in 415 patien ...... ent prognostic impact in CMML.
@en
P2093
A Pardanani
C A Hanson
M M Patnaik
R A Knudson
R P Ketterling
R R Laborde
P2860
P2888
P304
P356
10.1038/LEU.2013.97
P577
2013-04-05T00:00:00Z
P5875
P6179
1023877823